Portfolio Companies

Invested in innovative therapies

= Acquired Investment

= IPO/Reverse Merger

Private Companies

A2 Bio is developing a powerful & precise T cell therapy platform (Tmod™) that attacks solid tumors while sparing normal cells.

Abata Therapeutics is using antigen-directed natural thymic Treg cells to develop a curative autologous cell therapy for diseases such as Progressive MS and Type 1 Diabetes.

Abcuro, Inc. is a clinical stage biotechnology company developing first-in-class immunotherapies for autoimmune diseases and cancer through precise modulation of T and NK cells that express KLRG1 (killer cell lectin like receptor G1).

Alamar Biosciences is commercial proteomics company whose NULISA platform offer unrivalled precision, sensitivity and simplicity.

Alpha9 is developing potential best-in-class targeted radiopharmaceuticals for the treatment of cancer.

Autobahn Labs accelerates the translation of novel science to realize the potential of academic research. 

B3AR Therapeutics

Novel fixed-dose coformulation of B3 agonist & anti-muscarinic for the treatment of overactive bladder.

Bionic Sight’s technology focuses on restoring sight to patients with advanced stage blindness due to retinal degenerative diseases.

Codex Health develops clinical intelligence solutions for healthcare providers to bring the power of data-driven decision making into healthcare workflows.

Continuem Therapeutics (FKA: Pipeline Therapeutics) is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair.

Delfi utilizes novel machine learning algorithms to analyze fragments of cell-free DNA, resulting in the accurate detection of cancer from a single blood sample. Their product FirstLook, for early detection of lung cancer launched in 2023.

Dewpoint Therapeutics is developing a drug platform that targets biomolecular condensates, to pave the way for new approaches to treating the toughest diseases.

Elevatebio is creating and operating a portfolio of cell and gene therapy companies to develop, manufacture and commercialize life-transforming medicines.

Enara is developing therapies targeting Dark Antigens, a novel and differentiated class of cancer-specific targets from the genomic dark matter.

Enlaza is developing first-in-class covalent protein therapeutics to transform the treatment of cancer and other serious diseases.

Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets.

EyeBio is a clinical-stage ophthalmology biotech company delivering a clinical stage next-generation pipeline for back-of-the-eye diseases.

Fluent is commercial stage life-sciences tools company, with a propietary technology enabling powerful single cell analysis in every laboratory without the use of complex instrumentation.

Genalyte delivers rapid, actionable results to physicians through decentralized laboratory testing, backed by remote Telehealth oversight and monitoring.

ImmunOs is a clinical stage company developing novel therapeutics that leverage the HLA system to modulate the immune system for the treatment of cancer and autoimmune diseases.

IntegerBio is new immunovirology company harnessing the power of science, at the intersection of immunology and virology, to design broad therapeutics with durable response across multiple viruses.

Ionpath is a commercial stage life-science tools company based on MIBI, a mass spectrometry based imaging platform that permits 50+ biomolecules (proteins, DNA, RNA) to be measured simultaneously on a single tissue selection with resolution surpassing light microscopy.

Link Cell Therapies is developing a breakthrough logic-gate technology to enable the development of CAR-T for patients with solid tumors.

Medikine discovers and develops cytokine mimetics, or proteins that mimic the functions of cytokines, for the treatment of serious diseases.

MiroBio developing novel, best-in-class therapeutics that bring significant benefits to patients suffering from a range of auto-immune diseases.

Nalo’s mission is to address unmet needs in cancer by developing therapeutics targeting oncogenic driver mutations and/or proteins that are well-known but often hard to drug.

Neurogastrx is developing trasnformative therapies to advance the treatment of GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden.

Nikang Therapeutics is a clinical-stage biotech company dedicated to developing innovative small molecule drugs against high-value targets for oncology.

Nura, AKA: Proneurotech, is aspiring to develop disease modifying therapeutics to improve the lives of patient and families struggling with neurodegenerative disorders.

OnKure is engaged in the discovery and development of targeted small molecule therapies for the treatment of cancer that include selective mutant specific inhibitors of PI3K for the treatment of breast cancer.

OrsoBio is developing novel approaches to treat patients with severe metabolic disorders, including obesity, diabetes, severe dyslipidemias, NASH, and more.

Palvella Therapeutics is a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for serious genetic diseases with no approved treatments.

Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases.

Remplir Bio is developing therapeutics to reinvigorate exhausted T-cells by modulating solute carriers.

Respira is developing next-generation cardiopulmonary disease-targeted inhalation products.

Septerna is leading the way with potential best-in-class GPCR drug discovery enabled by differentiated native complex-based platforms.

Spyglass Pharma is developing a controlled release drug delivery platform for ophthalmic applications starting with glaucoma.

Synthekine is a clinical-stage company focused on discovery and developing best-in-lass cytokine therapeutics.

Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology.

Upstream Bio develops therapies that treat inflammatory and allergic diseases with their lead asset, an anti-TSLPR monoclonal antibody in phase II study.

Public Companies

Abivax (ABVX) is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.

Acelyrin (SLRN) is a late-stage clinical biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising product candidates.

Allakos, Inc. (ALLK) is a clinical-stage company developing antibodies that target receptor molecules present on the surface of immune effector cells involved in allergy, inflammation, tissue damage and proliferative disorders.

Arcellx, Inc. (ACLX) is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer.

Avadel Pharmaceuticals (AVDL) is a biopharmaceutical company that develops medications for narcolepsy and other disorders.

Bolt Biotherapeutics, Inc (BOLT) is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems.

CARGO (CARA), launched by Samsara in partnership with CAR T pioneers, is advancing a clinically validated CD22 CAR T for lymphoma.

Chinook Therapeutics, Inc. (KDNY) is a biotechnology company developing precision medicines for kidney diseases.

Decibel Therapeutics, Inc. (DBTX) is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine.

DICE Therapeutics (DICE) is a clinical-stage biopharmaceutical company combining innovative chemistry with well-validated biology to make medicines more accessible for people living with chronic autoimmune and inflammatory diseases.

Forma Therapeutics (FMTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers.

HilleVax (HLVX) is a biopharmaceutical company focused on the development and commercialization of novel vaccines.

Intercept Pharmaceuticals, Inc. (ICPT) focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry.

IO Biotech (IOBT) is a clinical-stage biopharmaceutical company pioneering the discovery and development of novel and highly differentiated immune-oncology therapeutics based on its proprietary technology platform, T-win®, which enables the activation of T cells that specifically target the immuno-suppressive tumor microenvironment.

IVERIC bio (ISEE) is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs.

Janux Therapeutics, Inc. (JANX) is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer.

(LPTX) Leap Therapeutics is focused on developing targeted immuno-oncology therapeutics. Their lead agent is in phase II studies in gastric and colorectal cancers.

LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision.

Lyra Therapeutics (LYRA) is a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS).

Mineralys Therapeutics, Inc. (MLYS) is a clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension.

Neurogene (NGNE) is accelerating development of new genetic medicines to people with devastating neurological diseases.

Nkarta Therapeutics (NKTX) is developing allogeneic or off-the-shelf cell therapies for cancer and auto-immune disease based on Natural Killer (NK) cells.

Pepgen (PEPG) is developing potentialbest-in-class peptide-conjugated oligonucleotides for treatment of neuromuscular disorders.

Prime Medicine (PRME) is delivering a new class of curative genetic therapies to address a wide spectrum of diseases by deploying Prime Editing technology.

RayzeBio (RYZB) is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes.

Scholar Rock (SRRK) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases by targeting the Transforming Growth Factor Beta pathway.

Sutro Biopharma (STRO) is a clinical-stage company developing next generation antibody drug conjugates (ADCs) for the treatment of cancer using their proprietary cell-free protein manufacturing technology.

Syros Pharmaceuticals, Inc. (SYRS) is advancing a new wave of medicines to control the expression of disease-driving genes.

Zymeworks (ZYME) is developing novel medicines for patients with difficult-to-treat cancers and other serious diseases.